Marja Rutgers

596 total citations
29 papers, 502 citations indexed

About

Marja Rutgers is a scholar working on Neurology, Oncology and Cancer Research. According to data from OpenAlex, Marja Rutgers has authored 29 papers receiving a total of 502 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Neurology, 10 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Marja Rutgers's work include Neuroblastoma Research and Treatments (13 papers), Cancer, Hypoxia, and Metabolism (9 papers) and Neuroendocrine Tumor Research Advances (5 papers). Marja Rutgers is often cited by papers focused on Neuroblastoma Research and Treatments (13 papers), Cancer, Hypoxia, and Metabolism (9 papers) and Neuroendocrine Tumor Research Advances (5 papers). Marja Rutgers collaborates with scholars based in Netherlands, Switzerland and Japan. Marja Rutgers's co-authors include Wouter W. de Herder, Theo J. Visser, F. Bonthuis, Lou A. Smets, M. P. Hazenberg, T.J. Visser, C.A. Hoefnagel, T. J. Visser, P.A. Voûte and Godelieve A.M. Tytgat and has published in prestigious journals such as Journal of Clinical Investigation, Endocrinology and British Journal of Cancer.

In The Last Decade

Marja Rutgers

29 papers receiving 492 citations

Peers

Countries citing papers authored by Marja Rutgers

Since Specialization

Citations

This map shows the geographic impact of Marja Rutgers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marja Rutgers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marja Rutgers more than expected).

Fields of papers citing papers by Marja Rutgers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marja Rutgers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marja Rutgers. The network helps show where Marja Rutgers may publish in the future.

Co-authorship network of co-authors of Marja Rutgers

This figure shows the co-authorship network connecting the top 25 collaborators of Marja Rutgers. A scholar is included among the top collaborators of Marja Rutgers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marja Rutgers. Marja Rutgers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake 2020 ·EJNMMI Research ·(unknown), Rutger Meinsma, Marja Rutgers, (unknown), (unknown), André B. P. Kuilenburg, Godelieve A.M. Tytgat	4
2	Human megakaryocytes cultured in vitro accumulate serotonin but not meta-iodobenzylguanidine whereas platelets concentrate both 2002 ·Experimental Hematology ·Godelieve A.M. Tytgat, (unknown), P.A. Voûte, Lou A. Smets, Marja Rutgers	8
3	A comparison of targetting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients 2001 ·European Journal of Nuclear Medicine and Molecular Imaging ·Cornelis A. Hoefnagel, Marja Rutgers, (unknown), Lou A. Smets, (unknown), Marina L. Meli, (unknown), Hanspeter Amstutz, P. August Schubiger, Ilse Novak‐Hofer	40
4	Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: Tissue distribution, metabolism and therapeutic efficacy 2000 ·International Journal of Cancer ·Marja Rutgers, (unknown), C.A. Hoefnagel, P.A. Voûte, Lou A. Smets	21
5	Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice 2000 ·Annals of Oncology ·Babs G. Taal, C.A. Hoefnagel, Henk Boot, R.A. Valdés Olmos, Marja Rutgers	23
6	[131I]- and [125I]metaiodobenzylguanidine therapy in macroscopic and microscopic tumors:A comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts 2000 ·International Journal of Cancer ·Marja Rutgers, (unknown), Martin A. van der Valk, C.A. Hoefnagel, P.A. Voûte, Lou A. Smets	12
7	Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG) 1999 ·British Journal of Cancer ·(unknown), Marja Rutgers, Martin A. van der Valk, Jos H. Beijnen, Lou A. Smets	5
8	Chemical characterization and comparative cellular effects of meta-iodobenzyl guanidine and benzyl guanidine 1997 ·Cancer Chemotherapy and Pharmacology ·(unknown), Lou A. Smets, Marja Rutgers, (unknown), Roel H. Fokkens, (unknown), (unknown)	7
9	Meta-iodobenzylguanidine uptake in platelets, megakaryoblastic leukaemia cell lines MKPL-1 and CHRF-288-11 and erythroleukaemic cell line HEL 1995 ·European Journal of Cancer ·Godelieve A.M. Tytgat, P.A. Voûte, (unknown), Ichiro Miyoshi, Marja Rutgers	8
10	Uptake of the neuron‐blocking agent meta‐iodobenzylguanidine and serotonin by human platelets and neuro‐adrenergic tumour cells 1993 ·International Journal of Cancer ·Marja Rutgers, Godelieve A.M. Tytgat, Manon Verwijs-Janssen, (unknown), Lou A. Smets, P.A. Voûte	23
11	Pharmacokinetics and intracellular distribution of the tumor‐targeted radiopharmaceutical m‐iodo‐benzylguanidine in SK‐N‐SH neuroblastoma and PC‐12 pheochromocytoma cells 1991 ·International Journal of Cancer ·Lou A. Smets, (unknown), Marja Rutgers, (unknown), (unknown)	36
12	Identification of 3,3′-Diiodothyroacetic Acid Sulfate: A Major Metabolite of 3,3′,5-Triiodothyronine in Propylthiouracil-Treated Rats* 1990 ·Endocrinology ·Marja Rutgers, (unknown), F. Bonthuis, (unknown), Theo J. Visser	3
13	Effects of Propylthiouracil on the Biliary Clearance of Thyroxine (T₄) in Rats: Decreased Excretion of 3,5,3′- Triiodothyronine Glucuronide and Increased Excretion of 3,3′,5′-Triiodothyronine Glucuronide and T₄Sulfate* 1989 ·Endocrinology ·Marja Rutgers, (unknown), F. Bonthuis, Roel Docter, Theo J. Visser	33
14	Increased Plasma 3,5,3'-Triiodothyronine Sulfate in Rats with Inhibited Type I Iodothyronine Deiodinase Activity, as Measured by Radioimmunoassay* 1989 ·Endocrinology ·(unknown), Ellen Kaptein, Marja Rutgers, Theo J. Visser	25
15	Metabolism of Triiodothyroacetic Acid (TA₃) in Rat Liver. II. Deiodination and Conjugation of TA₃by Rat Hepatocytes and in Ratsin Vivo* 1989 ·Endocrinology ·Marja Rutgers, (unknown), F. Bonthuis, T.J. Visser	13
16	On the enterohepatic cycle of triiodothyronine in rats; importance of the intestinal microflora 1989 ·Life Sciences ·Wouter W. de Herder, M. P. Hazenberg, (unknown), (unknown), Marja Rutgers, T. J. Visser	29
17	Metabolism of Triiodothyroacetic Acid (TA₃) in Rat Liver. I. Deiodination of TA₃and TA₃Sulfate by Microsomes* 1989 ·Endocrinology ·Marja Rutgers, (unknown), T.J. Visser	16
18	Enterohepatic Circulation of Triiodothyronine (T₃) in Rats: Importance of the Microflora for the Liberation and Reabsorption of T₃from Biliary T₃Conjugates* 1989 ·Endocrinology ·Marja Rutgers, (unknown), F. Bonthuis, Wouter W. de Herder, M. P. Hazenberg, Theo J. Visser	42
19	Effects of Inhibition of Type I Iodothyronine Deiodinase and Phenol Sulfotransferase on the Biliary Clearance of Triiodothyronine in Rats* 1988 ·Endocrinology ·Wouter W. de Herder, F. Bonthuis, Marja Rutgers, (unknown), M. P. Hazenberg, T.J. Visser	31
20	[The value of studies on the clotting mechanism for the diagnosis of liver diseases. II. Hepatitis and fibrinolysis]. 1965 ·PubMed ·S.I. de Vries, Marja Rutgers	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact